Equities research analysts at StockNews.com began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) in a research report issued on Monday. The firm set a “sell” rating on the stock.
Ampio Pharmaceuticals Stock Performance
AMPE stock opened at $0.13 on Monday. Ampio Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $8.30. The company has a 50-day moving average price of $0.24 and a 200 day moving average price of $1.17. The stock has a market cap of $148,200.00, a PE ratio of -0.01 and a beta of 2.15.
Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($2.48) EPS for the quarter.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Featured Stories
- Five stocks we like better than Ampio Pharmaceuticals
- What is an Earnings Surprise?
- Micron Technology Stock Volatile Despite Analyst Upgrades
- Are Penny Stocks a Good Fit for Your Portfolio?
- McDonald’s Stock: Balancing Value and Innovation
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 6/17 – 6/21
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
